Hu, K.; Xia, Y.; Yuan, T.; Lin, Y.; Yang, J.
Pharmacodynamic-Driven Sequence-Dependent Synergy Effects in Pemetrexed-Osimertinib Combination Against Non-Small Cell Lung Cancer (NSCLC): Optimizing Synergy Through Sequential Interval. Pharmaceutics 2025, 17, 1044.
https://doi.org/10.3390/pharmaceutics17081044
AMA Style
Hu K, Xia Y, Yuan T, Lin Y, Yang J.
Pharmacodynamic-Driven Sequence-Dependent Synergy Effects in Pemetrexed-Osimertinib Combination Against Non-Small Cell Lung Cancer (NSCLC): Optimizing Synergy Through Sequential Interval. Pharmaceutics. 2025; 17(8):1044.
https://doi.org/10.3390/pharmaceutics17081044
Chicago/Turabian Style
Hu, Kuan, Yu Xia, Tong Yuan, Yan Lin, and Jin Yang.
2025. "Pharmacodynamic-Driven Sequence-Dependent Synergy Effects in Pemetrexed-Osimertinib Combination Against Non-Small Cell Lung Cancer (NSCLC): Optimizing Synergy Through Sequential Interval" Pharmaceutics 17, no. 8: 1044.
https://doi.org/10.3390/pharmaceutics17081044
APA Style
Hu, K., Xia, Y., Yuan, T., Lin, Y., & Yang, J.
(2025). Pharmacodynamic-Driven Sequence-Dependent Synergy Effects in Pemetrexed-Osimertinib Combination Against Non-Small Cell Lung Cancer (NSCLC): Optimizing Synergy Through Sequential Interval. Pharmaceutics, 17(8), 1044.
https://doi.org/10.3390/pharmaceutics17081044